Boston, MA · Founded 2025 · Privately Held (backing)
Operator of a biotechnology company intended to develop first-in-class precision medicines targeting previously undruggable cancer and serious disease targets. Antares Therapeutics is based in Boston, MA and was founded in 2025. It is valued at about $299 million as of Oct 2026, set by institutional fund marks. It has raised $177 million across 2 recorded rounds; the latest was a $30 million early-stage round in May 2025.
PMV mark · valuation
$299.0M
Oct 2026
Priced at
its early-stage round
Apr 2025
Total raised
$177.0M
Last round
Early Stage VC
May 2025
Cap table — not yet on record
Antares Therapeutics's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.
Pro members can request priority coverage with a 48-hour turnaround.
Where does Antares Therapeutics's cap table come from?
Share classes are assembled from certificates of incorporation, priced-round filings, and disclosures across Antares Therapeutics's 2 recorded funding rounds.
